Key facts
- NETRI’s last known valuation is $64.2M (Feb 2025).
- It has raised $14.6M; the latest was Later Stage VC ($5.2M) in Feb 2025.
- Notable investors include Bpifrance, Banque Publique d'Investissement, Clery, Merck Digital Sciences Studio, Neovacs — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for NETRI
- ·The full record, as it builds
Funding rounds
No funding rounds for NETRI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NETRI
Developer of biological research tools designed to simulate human biology for drug testing. The company's tools combine human neural stem cells, organs-on-chip technology, and AI-driven algorithms to reproduce neural data, enabling researchers to assess drug efficacy and toxicity, and diagnose diseases by analyzing digital signatures, offering customizable models for food safety, pain management, dermatology, and neurodegenerative disorders.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2018
- Employees
- 35
- Website
- netri.com/
- Ownership
- Privately Held (backing)
NETRI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NETRI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NETRI in its N-PORT filings yet. We sweep new filings monthly.